Loading…
Low Carb Breckenridge 2017 is open to all including the general public, health, nutrition and fitness enthusiasts, scientific community and healthcare professionals.

For healthcare professionals, this live activity, Low Carb Breckenridge 2017, with a beginning date of 02/24/2017, has been reviewed and is acceptable for up to 19.25 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity. AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

Event Page: http://denversdietdoctor.com/low-carb-breckenridge-2017/
Saturday, February 25 • 10:30am - 11:00am
Nutrition Therapy of Non-Alcoholic Liver Disease – The Most Convincing Argument for Low-Carb Eating (CME Approved)

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Feedback form is now closed.
Nonalcoholic fatty liver disease (NAFLD) is defined as hepatic steatosis without significant alcohol-related or other cause of secondary steatosis, and is the most widespread liver disease in the industrialised world with around 20 – 30 % of the global population affected. NAFLD ranges from steatosis on its own (NAFL) to nonalcoholic steatohepatitis (NASH) and cirrhosis, and on towards hepatocellular carcinoma (HCC). NAFLD development is multifactorial with influences including genetic and epigenetic, hormonal and environmental factors, and especially lifestyle with a hypercaloric energy dense high refined-carbohydrate intake. Peripheral and hepatic insulin resistance is a common link to the established risk factors that include visceral obesity, hypercaloric diet, and lack of physical activity. NAFLD is not an isolated liver disease as it causes a variety of metabolic disorders including type 2 diabetes, kidney disease, and atherosclerotic issues such as coronary heart disease. NAFLD is diagnosed using imaging procedures, especially sonography, and biochemical and anthropometric data in routine clinical practice; treatment involves lifestyle intervention consisting of exercise and nutritional therapy. Both weight loss and changes in diet are independently associated with improvement in the liver in NAFLD. However a low-carbohydrate mediterranean style diet is beneficial even when weight reduction is not achieved.

Speakers

Saturday February 25, 2017 10:30am - 11:00am MST
1) Forrest Room